Weight-Loss Drug Wegovy Launches In U.K. As Shares Of Drugmaker Novo Nordisk Hit New Peak
In August, Novo Nordisk's CEO said it could “take quite some years” for the company to meet soaring demand for the popular drug.
Novo Nordisk launches weight-loss drug Wegovy in UK
Novo Nordisk launched its weight-loss injection Wegovy in Britain on Monday, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to k...
Novo Nordisk briefly becomes Europe's No1 as investors binge on weight-loss stocks
Novo Nordisk (NYSE:NVO) became Europe's largest company for a short time today as investors continued to pile into the Danish drugmaker following the recent trial of fat-busting drug Wegovy. Shares...
Ozempic could be the next target of Medicare drug price negotiations – here's why
Wall Street analysts expect Ozempic to be selected for price negotiations in 2025 due to the amount of money Medicare Part D already spends on the drug.
Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
Novo Nordisk is making strides in the weight loss and diabetes care markets, with strong financial performance and a diverse product portfolio. The company faces competition from Eli Lilly's GLP-1 ...
Novo Nordisk CEO: Not exactly clear yet what Medicare price negotiations will do for financials
Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Squawk on the Street' to discuss what's known about the White House's negotiations for specific drug prices, long-term worries about suppressed R...
Wegovy Maker Novo Nordisk Buys Embark Biotech to Boost Edge in Weight Loss Treatments
Wegovy maker Novo Nordisk (NVO) agreed to buy Embark Biotech for €15 million ($16 million) in cash upfront, in a move that could boost Novo Nordisk's portfolio of weight loss treatments. In additio...
Insulins and blood thinners among first 10 drugs up for Medicare price negotiations
The Biden administration has revealed the first 10 prescription drugs that will be subject to price negotiations between manufacturers and the U.S. health program Medicare with the aim of reducing ...
Novo Nordisk (NVO) Posts Upbeat Data From Heart Failure Study
Novo Nordisk (NVO) announces positive results from its label-expanding study of Wegovy to treat patients with heart failure and obesity.
Novo Nordisk's Wegovy Helped Heart-Failure Patients. What's Next?
Proof that new weight-loss drugs will transform healthcare was bolstered with the news that heart-failure patients were helped by Novo Nordisk's drug Wegovy.
Novo Nordisk obesity drug Wegovy eases symptoms of heart failure, study finds
The Novo Nordisk NVO, -2.47% obesity drug semaglutide, marketed as Wegovy, can significantly reduce symptoms related to heart failure, according to a study published Friday in the New England Journ...
Novo Nordisk CEO Lars Fruergaard Jorgensen at Reuters Newsmaker event
Novo Nordisk CEO Lars Fruergaard Jorgensen spoke at a Reuters Newsmaker event on Friday. Below are some quotes from his interview which focused on the company's hugely popular Wegovy weight-loss drug.
Novo Nordisk to address social inequality in dialogue with healthcare systems -CEO
Novo Nordisk CEO Lars Fruergaard Jorgensen said on Friday the company will work with European government healthcare systems to ensure less fortunate and the most obese people get access to its Wego...
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
The active ingredient in Ozempic could be useful for quite a few conditions. Cardiovascular disease, certain chronic liver diseases, and addiction are just a few.
Why Novo Nordisk Stock Was Racing Higher on Wednesday
Not surprisingly, this had to do with its highly popular weight-loss drug. A second contract manufacturer for Wegovy has been identified.
Related Companies